Replication-competent vectors and empty virus-like particles: new retroviral vector designs for cancer gene therapy or vaccines. (Q36716418)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17245356%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

review article

1 reference

title

Replication-competent vectors and empty virus-like particles: new retroviral vector designs for cancer gene therapy or vaccines (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17245356%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

0 references

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17245356%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

David Klatzmann

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17245356%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

author name string

Charlotte Dalba

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17245356%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Noriyuki Kasahara

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17245356%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

publication date

23 January 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17245356%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17245356%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17245356%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17245356%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

page(s)

457-466

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17245356%20AND%20SRC:MED&resulttype=core&format=json

Introduction of a selectable gene into different animal tissue by a retrovirus recombinant vector

24 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Construction and applications of a highly transmissible murine retrovirus shuttle vector

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Retrovirus packaging cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Construction of a retroviral vector production system with the minimum possibility of a homologous recombination

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Gene therapy for severe combined immunodeficiencies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Occurrence of leukaemia following gene therapy of X-linked SCID.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

The role of LMO2 in development and in T cell leukemia after chromosomal translocation or retroviral insertion

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Integration target site selection for retroviruses and transposable elements.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Fragile sites are preferential targets for integrations of MLV vectors in gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Gene therapy: therapeutic gene causing lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Clinical trials with retrovirus mediated gene therapy--what have we learned?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Immune mechanisms associated with protection from vaginal SIV challenge in rhesus monkeys infected with virulence-attenuated SHIV 89.6.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Replication-selective oncolytic viruses in the treatment of cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Oncolytic virotherapy for cancer treatment: challenges and solutions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Beyond oncolytic virotherapy: replication-competent retrovirus vectors for selective and stable transduction of tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Construction of a replication-competent murine retrovirus vector expressing the human immunodeficiency virus type 1 tat transactivator protein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Construction and properties of replication-competent murine retroviral vectors encoding methotrexate resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Replication-competent Moloney murine leukemia virus carrying a bacterial suppressor tRNA gene: selective cloning of proviral and flanking host sequences

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Replicative retroviral vectors for cancer gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Expression of heterologous genes from an IRES translational cassette in replication competent murine leukemia virus vectors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Genomic stability of murine leukemia viruses containing insertions at the Env-3' untranslated region boundary

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

A uniquely stable replication-competent retrovirus vector achieves efficient gene delivery in vitro and in solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

A replication-competent feline leukemia virus, subgroup A (FeLV-A), tagged with green fluorescent protein reporter exhibits in vitro biological properties similar to those of the parental FeLV-A

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Highly efficient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Eradication of murine brain tumors by direct inoculation of concentrated high titer-recombinant retrovirus harboring the herpes simplex virus thymidine kinase gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Characterization of a semi-replicative gene delivery system allowing propagation of complementary defective retroviral vectors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Cell targeting by murine retroviral vectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

T cell-specific expression from Mo-MLV retroviral vectors containing a CD4 mini-promoter/enhancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Transcriptionally targeted retroviral vector for combined suicide and immunomodulating gene therapy of thyroid cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Tight control of transgene expression by lentivirus vectors containing second-generation tetracycline-responsive promoters.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Homologous recombination and gene targeting

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Gene therapy progress and prospects: targeted gene repair

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Psi- vectors: murine leukemia virus-based self-inactivating and self-activating retroviral vectors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Retroviral gene therapy: safety issues and possible solutions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors--design, biosafety, and production.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Retrovirus vectors: toward the plentivirus?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Retroviral elements and their hosts: insertional mutagenesis in the mouse germ line

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Papio cynocephalus endogenous retrovirus among old world monkeys: evidence for coevolution and ancient cross-species transmissions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Packaging of endogenous retroviral sequences in retroviral vectors produced by murine and human packaging cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Improving the safety of a conditional-live human immunodeficiency virus type 1 vaccine by controlling both gene expression and cell entry

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Virus-like particles as immunogens

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Virus-like particles: a new family of delivery systems

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Particle-based vaccines for HIV-1 infection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Virus-like particles as HIV-1 vaccines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Analysis of protein expression and virus-like particle formation in mammalian cell lines stably expressing HIV-1 gag and env gene products with or without active HIV proteinase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Virus-like particle and DNA-based candidate AIDS vaccines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Accelerated clearance of SHIV in rhesus monkeys by virus-like particle vaccines is dependent on induction of neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Noninfectious virus-like particles produced by Moloney murine leukemia virus-based retrovirus packaging cells deficient in viral envelope become infectious in the presence of lipofection reagents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Murine leukemia virus particle assembly quantitated by fluorescence microscopy: role of Gag-Gag interactions and membrane association

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Intracellular trafficking of Gag and Env proteins and their interactions modulate pseudotyping of retroviruses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

A block to human immunodeficiency virus type 1 assembly in murine cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

The influence of antigen organization on B cell responsiveness

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

The proline-rich region of the ecotropic Moloney murine leukaemia virus envelope protein tolerates the insertion of the green fluorescent protein and allows the generation of replication-competent virus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

DNA vaccines encoding retrovirus-based virus-like particles induce efficient immune responses without adjuvant.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Targeted gene transfer to lymphocytes using murine leukaemia virus vectors pseudotyped with spleen necrosis virus envelope proteins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Intracellular versus cell surface assembly of retroviral pseudotypes is determined by the cellular localization of the viral glycoprotein, its capacity to interact with Gag, and the expression of the Nef protein.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Superior transduction of mouse hematopoietic stem cells with 10A1 and VSV-G pseudotyped retrovirus vectors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Optimization of gene transfer into primitive human hematopoietic cells of granulocyte-colony stimulating factor-mobilized peripheral blood using low-dose cytokines and comparison of a gibbon ape leukemia virus versus an RD114-pseudotyped retroviral

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Transduction efficiency of MLV but not of HIV-1 vectors is pseudotype dependent on human primary T lymphocytes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Loading of MHC class I and II presentation pathways by exogenous antigens: a quantitative in vivo comparison.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Dendritic cells, infected with vesicular stomatitis virus-pseudotyped HIV-1, present viral antigens to CD4+ and CD8+ T cells from HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

MHC-I-restricted presentation of HIV-1 virion antigens without viral replication

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Regulation of antigen presentation and cross-presentation in the dendritic cell network: facts, hypothesis, and immunological implications.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Recombinant viruses as vaccines against viral diseases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Budding and secretion of HIV Gag-Env virus-like particles from recombinant human adenovirus infected cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Characterization of a DNA vaccine expressing a human immunodeficiency virus-like particle

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Molecular and biological characterization of simian-human immunodeficiency virus-like particles produced by recombinant fowlpox viruses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02_AG) DNA/MVA vaccines expressing mature and immature VLPs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Integration of viral genomes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

A non-retroviral RNA virus persists in DNA form

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300054

7 January 2021

Identifiers

DOI

10.1038/SJ.MT.6300054

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17245356%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

1 reference